Subscribe To
MGTX / MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Misses Revenue Estimates
MGTX News
By Proactive Investors
October 30, 2023
MeiraGTx shares take off on $30M investment by Sanofi
MeiraGTx Holdings PLC (NASDAQ:MGTX) shares gained more than 25% after it announced Sanofi SA (ADR) (NYSE:SNY), a pharma giant best known for its vacci more_horizontal
By Market Watch
October 30, 2023
MeiraGTx shares jump as Sanofi invests in gene therapy
Shares of MeiraGTx Holdings PLC MGTX, -4.88% jumped 14% premarket on Monday after the gene therapy company announced that French drugmaker Sanofi SNY, more_horizontal
By Zacks Investment Research
August 10, 2023
MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Misses Revenue Estimates
MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares t more_horizontal
By Zacks Investment Research
June 29, 2023
MeiraGTx Holdings PLC (MGTX) Soars 8.2%: Is Further Upside Left in the Stock?
MeiraGTx Holdings PLC (MGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revis more_horizontal
By Zacks Investment Research
June 2, 2023
Does MeiraGTx Holdings PLC (MGTX) Have the Potential to Rally 320.9% as Wall Street Analysts Expect?
The consensus price target hints at a 320.9% upside potential for MeiraGTx Holdings PLC (MGTX). While empirical research shows that this sought-after more_horizontal
By GlobeNewsWire
December 8, 2022
MeiraGTx to Present Clinical Data from Phase 1 Trial of AAV-hAQP1 for Radiation-Induced Xerostomia on Tuesday, December 13, 2022
LONDON and NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy more_horizontal